{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:34:57Z","timestamp":1789472097991,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicalradiologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Radiology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.crad.2025.106915","type":"journal-article","created":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T20:22:10Z","timestamp":1743625330000},"page":"106915","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Prediction of PD-L1 expression in NSCLC patients using PET\/CT radiomics and prognostic modelling for immunotherapy in PD-L1-positive NSCLC patients"],"prefix":"10.1016","volume":"86","author":[{"given":"M.","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4379-9348","authenticated-orcid":false,"given":"L.","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.crad.2025.106915_bib1","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ijrobp.2020.01.032","article-title":"Absolute lymphocyte count predicts abscopal responses and outcomes in patients receiving combined immunotherapy and radiation therapy: analysis of 3 phase 1\/2 trials","volume":"108","author":"Chen","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.crad.2025.106915_bib2","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.crad.2025.106915_bib3","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.21.01497","article-title":"First-line immunotherapy for non-small-cell lung cancer","volume":"40","author":"Reck","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.crad.2025.106915_bib4","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.crad.2025.106915_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11020201","article-title":"The role of molecular profiling to predict the response to immune checkpoint inhibitors in lung cancer","volume":"11","author":"Kaderbha\u00ef","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.crad.2025.106915_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103582","article-title":"PD-L1 expression and Tumour mutation burden as Pathological response biomarkers of Neoadjuvant immunotherapy for Early-stage Non-small cell lung cancer: a systematic review and meta-analysis","volume":"170","author":"Deng","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.crad.2025.106915_bib7","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.crad.2025.106915_bib8","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.lungcan.2017.09.010","article-title":"PD-L1 IHC in NSCLC with a global and methodological perspective","volume":"113","author":"Thunnissen","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.crad.2025.106915_bib9","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1200\/JCO.2017.75.3384","article-title":"Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing","volume":"36","author":"Rizvi","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.crad.2025.106915_bib10","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1001\/jamaoncol.2015.3638","article-title":"Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer","volume":"2","author":"McLaughlin","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.crad.2025.106915_bib11","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3389\/fonc.2020.00349","article-title":"Intratumor heterogeneity in early lung adenocarcinoma","volume":"10","author":"Senosain","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.crad.2025.106915_bib12","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ejca.2011.11.036","article-title":"Radiomics: extracting more information from medical images using advanced feature analysis","volume":"48","author":"Lambin","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.crad.2025.106915_bib13","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00066-020-01625-9","article-title":"Radiomics and deep learning in lung cancer","volume":"196","author":"Avanzo","year":"2020","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.crad.2025.106915_bib14","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/14737140.2021.1852935","article-title":"Radiomics features as predictive and prognostic biomarkers in NSCLC","volume":"21","author":"Bortolotto","year":"2021","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.crad.2025.106915_bib15","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1055\/a-1816-6950","article-title":"Standardised 18F-FDG PET\/CT radiomic features provide information on PD-L1 expression status in treatment-na\u00efve patients with non-small cell lung cancer","volume":"61","author":"Zhang","year":"2022","journal-title":"Nuklearmedizin"},{"key":"10.1016\/j.crad.2025.106915_bib16","doi-asserted-by":"crossref","first-page":"5875","DOI":"10.21873\/anticanres.16096","article-title":"A machine learning approach using PET\/CT-based radiomics for prediction of PD-L1 expression in non-small cell lung cancer","volume":"42","author":"Lim","year":"2022","journal-title":"Anticancer Res"},{"key":"10.1016\/j.crad.2025.106915_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.789014","article-title":"Evaluation of PD-L1 expression level in patients with non-small cell lung cancer by (18)F-fdg PET\/CT radiomics and clinicopathological characteristics","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.crad.2025.106915_bib18","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1158\/0008-5472.CAN-18-0125","article-title":"LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity","volume":"78","author":"Nioche","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.crad.2025.106915_bib19","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1158\/0008-5472.CAN-17-0339","article-title":"Computational radiomics system to decode the radiographic phenotype","volume":"77","author":"van Griethuysen","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.crad.2025.106915_bib20","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00109-015-1376-x","article-title":"Immunosuppressive cells in tumour immune escape and metastasis","volume":"94","author":"Liu","year":"2016","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.crad.2025.106915_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.964442","article-title":"The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers","volume":"13","author":"Tang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.crad.2025.106915_bib22","doi-asserted-by":"crossref","DOI":"10.1177\/1534735419890020","article-title":"Current clinical progress of PD-1\/PD-L1 immunotherapy and potential combination treatment in non-small cell lung cancer","volume":"18","author":"Li","year":"2019","journal-title":"Integr Cancer Ther"},{"key":"10.1016\/j.crad.2025.106915_bib23","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","article-title":"Predictive biomarkers for checkpoint inhibitor-based immunotherapy","volume":"17","author":"Gibney","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.crad.2025.106915_bib24","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1200\/JCO.2017.74.3062","article-title":"Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057)","volume":"35","author":"Horn","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.crad.2025.106915_bib25","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.crad.2025.106915_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejro.2024.100549","article-title":"Deep learning radiomics model based on PET\/CT predicts PD-L1 expression in non-small cell lung cancer","volume":"12","author":"Li","year":"2024","journal-title":"Eur J Radiol Open"},{"key":"10.1016\/j.crad.2025.106915_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1402994","article-title":"Deep learning-based image analysis predicts PD-L1 status from (18)F-FDG PET\/CT images in non-small-cell lung cancer","volume":"14","author":"Liang","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.crad.2025.106915_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002118","article-title":"Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET\/CT images","volume":"9","author":"Mu","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.crad.2025.106915_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16173074","article-title":"Improving the clinical utility of platelet count for cancer detection in primary care: a cohort study in england, Canada, and Australia","volume":"16","author":"Mounce","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.crad.2025.106915_bib30","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/MNM.0000000000001517","article-title":"Correlation of epidermal growth factor receptor mutation status and PD-L1 expression with [18F]FDG PET using volume-based parameters in non-small cell lung cancer","volume":"43","author":"Ishimura","year":"2022","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.crad.2025.106915_bib31","article-title":"Soluble PD-L1 in NSCLC patients treated with checkpoint inhibitors and its correlation with metabolic parameters","volume":"12","author":"Castello","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.crad.2025.106915_bib32","doi-asserted-by":"crossref","first-page":"5889","DOI":"10.1007\/s00330-024-10651-5","article-title":"Predicting programmed death-ligand 1 (PD-L1) expression with fluorine-18 fluorodeoxyglucose ([(18)F]FDG) positron emission tomography\/computed tomography (PET\/CT) metabolic parameters in resectable non-small cell lung cancer","volume":"34","author":"Hughes","year":"2024","journal-title":"Eur Radiol"},{"key":"10.1016\/j.crad.2025.106915_bib33","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1093\/jnci\/djab116","article-title":"Smoking history as a potential predictor of immune checkpoint inhibitor efficacy in metastatic non-small cell lung cancer","volume":"113","author":"Wang","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.crad.2025.106915_bib34","doi-asserted-by":"crossref","first-page":"55","DOI":"10.21037\/tlcr.2020.01.03","article-title":"A detailed smoking history and determination of MYC status predict response to checkpoint inhibitors in advanced non-small cell lung cancer","volume":"9","author":"Chiu","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.crad.2025.106915_bib35","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1186\/s12885-020-07040-8","article-title":"A predictive model for treatment response in patients with locally advanced esophageal squamous cell carcinoma after concurrent chemoradiotherapy: based on SUVmean and NLR","volume":"20","author":"Wang","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.crad.2025.106915_bib36","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/RLU.0000000000000613","article-title":"Prognostic value of SUVmean in oropharyngeal and hypopharyngeal cancers: comparison with SUVmax and other volumetric parameters of 18F-FDG PET","volume":"40","author":"Pak","year":"2015","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.crad.2025.106915_bib37","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1111\/1759-7714.14103","article-title":"Elevations of monocyte and neutrophils, and higher levels of granulocyte colony-stimulating factor in peripheral blood in lung cancer patients","volume":"12","author":"Yin","year":"2021","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.crad.2025.106915_bib38","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1158\/1055-9965.EPI-08-0042","article-title":"Physical activity, white blood cell count, and lung cancer risk in a prospective cohort study","volume":"17","author":"Sprague","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.crad.2025.106915_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0159433","article-title":"Nutritional supplement of hatchery eggshell membrane improves poultry performance and provides resistance against endotoxin stress","volume":"11","author":"Makkar","year":"2016","journal-title":"PLoS One"}],"container-title":["Clinical Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009926025001205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009926025001205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T03:48:34Z","timestamp":1758685714000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009926025001205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":39,"alternative-id":["S0009926025001205"],"URL":"https:\/\/doi.org\/10.1016\/j.crad.2025.106915","relation":{},"ISSN":["0009-9260"],"issn-type":[{"value":"0009-9260","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prediction of PD-L1 expression in NSCLC patients using PET\/CT radiomics and prognostic modelling for immunotherapy in PD-L1-positive NSCLC patients","name":"articletitle","label":"Article Title"},{"value":"Clinical Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.crad.2025.106915","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd on behalf of The Royal College of Radiologists.","name":"copyright","label":"Copyright"}],"article-number":"106915"}}